Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation

被引:42
作者
Hilbrands, LB [1 ]
Hoitsma, AJ [1 ]
Koene, RAP [1 ]
机构
[1] UNIV NIJMEGEN HOSP,DIV NEPHROL,6500 HB NIJMEGEN,NETHERLANDS
关键词
D O I
10.1097/00007890-199604150-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cyclosporine (CsA) and prednisone (Pred) are the most widely used drugs for immunosuppression after renal transplantation, but both drugs have marked side effects. Either replacement of CsA by azathioprine (Aza) or withdrawal of prednisone (Pred) resulting in CsA monotherapy can be employed to circumvent the adverse effects in the long run. Both treatment regimens were compared in this prospective randomized trial in patients who were treated with CsA and Pred during the first 3 months after renal transplantation (CsA: n=64, Aza-Pred: n=63, median duration of follow-up: 3.9 years). Estimated graft survival rates at 5 years after transplantation (in patients with a functioning graft at 3 months) were 78% in the CsA group and 87% in the Aza-Pred group. The incidence of a rejection within 3 months after start of steroid withdrawal or conversion from CsA to Aza was 30% and 25%, respectively (NS). At 2 years after transplantation, serum creatinine levels were lower in the Aza-Pred group (126+/-35 mu mol/L) than in the CsA group (180+/-78 mu mol/L; P<0.001). There were no differences in blood pressure or incidence of infections between the treatment groups. Treatment-related costs were measured during the first year after transplantation and were lower in the Aza-Pred group (DFL 40,882+/-18,895 vs. DFL 53,484+/-44,828; 1 DFL [Dutch guilder] is about US $0.60; P<0.05). In conclusion, CsA monotherapy and Aza-Pred treatment from 3 months after renal transplantation are comparably effective immunosuppressive treatment regimens, although Aza-Pred therapy results in better graft function. Withdrawal of steroids and replacement of CsA by Aza both carry a substantial risk of rejection. The previously demonstrated cost effectiveness of CsA-containing therapies seems to be limited to the first phase after transplantation. Conversion to Aza-Pred at 3 months after transplantation reduces costs.
引用
收藏
页码:1038 / 1046
页数:9
相关论文
共 42 条
  • [11] COMPARISON OF 3 IMMUNOSUPPRESSIVE REGIMENS IN CADAVER RENAL-TRANSPLANTATION - LONG-TERM CYCLOSPORINE, SHORT-TERM CYCLOSPORINE FOLLOWED BY AZATHIOPRINE AND PREDNISOLONE, AND AZATHIOPRINE AND PREDNISOLONE WITHOUT CYCLOSPORINE
    HALL, BM
    TILLER, DJ
    HARDIE, I
    MAHONY, J
    MATHEW, T
    THATCHER, G
    MIACH, P
    THOMSON, N
    SHEIL, AGR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (23) : 1499 - 1507
  • [12] ELECTIVE CYCLOSPORINE WITHDRAWAL 1 YEAR AFTER RENAL-TRANSPLANTATION
    HEIMDUTHOY, KL
    CHITWOOD, KK
    TORTORICE, KL
    MASSY, ZA
    KASISKE, BL
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 24 (05) : 846 - 853
  • [13] ELECTIVE CONVERSION FROM CYCLOSPORINE TO AZATHIOPRINE IN SENSITIZED PATIENTS FOLLOWING CADAVERIC RENAL-TRANSPLANTATION
    HELLING, TS
    WOOD, BC
    NELSON, PW
    SHELTON, LL
    EISENSTEIN, CL
    CROUCH, TT
    SHARMA, JN
    MERTZ, JI
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1990, 15 (02) : 137 - 140
  • [14] HILBRANDS LB, 1995, TRANSPLANTATION, V59, P1263, DOI 10.1097/00007890-199505000-00007
  • [15] HILBRANDS LB, 1995, J AM SOC NEPHROL, V5, P2073
  • [16] HOITSMA AJ, 1988, TRANSPLANT P, V20, P161
  • [17] BENEFICIAL-EFFECTS OF CONVERSION FROM CYCLOSPORINE TO AZATHIOPRINE AFTER KIDNEY-TRANSPLANTATION
    HOLLANDER, AAMJ
    VANSAASE, JLCM
    KOOTTE, AMM
    VANDORP, WT
    VANBOCKEL, HJ
    VANES, LA
    VANDERWOUDE, FJ
    [J]. LANCET, 1995, 345 (8950): : 610 - 614
  • [18] HRICIK DE, 1993, J AM SOC NEPHROL, V4, P1300
  • [19] WITHDRAWAL OF STEROIDS AFTER RENAL-TRANSPLANTATION - CLINICAL PREDICTORS OF OUTCOME
    HRICIK, DE
    WHALEN, CC
    LAUTMAN, J
    BARTUCCI, MR
    MOIR, EJ
    MAYES, JT
    SCHULAK, JA
    [J]. TRANSPLANTATION, 1992, 53 (01) : 41 - 45
  • [20] JOHNSON RWG, 1989, TRANSPLANT P, V21, P1581